Pharmacological benefit of I1-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease

摘要: Huntington's disease (HD), a neurodegenerative disorder, is characterized by progressive motor dysfunction, emotional disturbances, dementia, weight loss and anxiety. The tremendous amount of research work required to identify new pharmacological agents therapeutic utility combat this condition. This study investigates the effect selective modulator I1-imidazoline receptor (moxonidine) as well nuclear factor kappa-B (NF-κB) (natrium diethyl dithio carbamate trihydrate-NDDCT) on 3-nitropropionic acid (3-NPA) induced experimental HD 3-NPA was used induce mitochondrial damage associated symptoms in rats. Anxiety assessed using Elevated plus maze-EPM learning-memory EPM Morris water maze-MWM. Different biochemical estimations were assess brain striatum oxidative stress (lipid peroxide, superoxide dismutase catalase), nitric oxide levels (nitrite/nitrate), cholinergic activity (brain acetyl cholinesterase activity), enzyme complex (I, II IV) activities. has anxiety, impaired with reduction body weight, locomotor activity, grip strength. It increased acetylcholinesterase-AChE nitrite/nitrate, catalase) Tetrabenazine-TBZ (monoamine storage inhibitor) positive control. Treatment moxonidine, NDDCT TBZ significantly attenuated strength, anxiety learning memory. Administration these various impairments. Therefore, modulation NF-κB may be considered potential for management HD.